title: Emerging therapeutic targets in psoriasis.
abstract: Biopharmaceuticals that target specific disease-mediating molecules have advanced our understanding of the pathogenesis of psoriasis. The traditional paradigm that psoriasis is primarily a disease of epidermal cells has been replaced with a model that now includes keratinocyte-derived factors, inflammatory mediators and angiogenic mechanisms. Recent studies have highlighted some of the key molecules involved in all of these pathogenic processes. Several have already been evaluated as putative targets in in vitro and in vivo studies, whereas other molecules are significantly upregulated in psoriasis and require further study to elucidate their role and contribution to disease. Although not all these molecules will eventually qualify as drug targets, data from similar experimental strategies are predicted to underpin the next generation of candidate targets and novel therapeutic approaches.
authors.affiliation: GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0DP, UK.
authors.forename: Andrew I
authors.initials: AI
authors.lastname: Bayliffe
authors.forename: Richard A
authors.initials: RA
authors.lastname: Brigandi
authors.forename: H Jeffrey
authors.initials: HJ
authors.lastname: Wilkins
authors.forename: Mark P
authors.initials: MP
authors.lastname: Levick
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects*; D011565:Psoriasis / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D016559:Tacrolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D042442:Vascular Endothelial Growth Factors / Q000009:adverse effects*
chemical_list: D020533:Angiogenesis Inhibitors; D003879:Dermatologic Agents; D042442:Vascular Endothelial Growth Factors; C117268:pimecrolimus; D016559:Tacrolimus